Correlation of Serum pANCA with Efficacy of Mesalazine on Ulcerative Colitis:A Preliminary Study
10.3969/j.issn.1008-7125.2014.12.009
- VernacularTitle:血清pANCA与美沙拉秦对溃疡性结肠炎治疗效果关系的初步研究
- Author:
Ziqiong LI
;
Feng GAO
- Publication Type:Journal Article
- Keywords:
Antibodies,Antineutrophil Cytoplasmic;
Aminosalicylic Acids;
Colitis,Ulcerative
- From:
Chinese Journal of Gastroenterology
2014;(12):739-741
- CountryChina
- Language:Chinese
-
Abstract:
Background:It has been demonstrated that serum perinuclear antineutrophil cytoplasmic antibody( pANCA)occurred significantly more often in ulcerative colitis( UC ) than in Crohn ’s disease( CD ),so it is of great importance for differential diagnosis of UC and CD. Aims:To study the correlation of serum pANCA with efficacy of aminosalicylic acids ( ASA)on UC. Methods:A retrospective study was conducted in 70 mild to moderate active UC patients admitted between Jan. 2007 and Dec. 2013 at People’s Hospital of Xinjiang Uygur Autonomous Region,all of them received oral mesalazine therapy,35 were positive and 35 were negative for serum pANCA. The efficacy was compared between the two groups. Results:After a four-week oral mesalazine therapy,the remission rate and overall efficacy were significantly higher in pANCA-positive group than in pANCA-negative group( remission rate:80. 0% us. 54. 3%,P﹤0. 05;overall efficacy:94. 3% us. 77. 1%,P﹤0. 05). Conclusions:Mesalazine is more effective in serum pANCA-positive UC patients. Being a specific immunological biomarker of UC,pANCA might be an indicator for predicting the therapeutic efficacy of ASA in UC patients.
